The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-screen: Efficient identification of cancer genome alterations in advanced esophageal cancer.
 
Yuichiro Nakashima
No Relationships to Disclose
 
Takashi Kojima
Honoraria - Amgen
Research Funding - Merck Serono (Inst)
Patents, Royalties, Other Intellectual Property - Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Hiroki Hara
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Merck Serono; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Ken Kato
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Merck Serono; MSD Oncology; Ono Pharmaceutical; Shionogi
 
Takeshi Kajiwara
No Relationships to Disclose
 
Shuichi Hironaka
No Relationships to Disclose
 
Hiroshi Nakatsumi
No Relationships to Disclose
 
Takeshi Kato
Speakers' Bureau - Chugai Pharma; Lilly; TAKEDA; Yakult Pharmaceutical
 
Toshikazu Moriwaki
Speakers' Bureau - Chugai Pharma; Merck Serono; Novelpharm; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Daisuke Naruge
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hisamitsu Pharmaceutical (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Kayaku (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Torii Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Taito Esaki
Honoraria - Chugai Pharma; Eisai; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (I)
 
Naoki Izawa
No Relationships to Disclose
 
Shigenori Kadowaki
Research Funding - Boehringer Ingelheim (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst)
 
Takao Tamura
No Relationships to Disclose
 
Izumi Miki
No Relationships to Disclose
 
Tomohisa Sudo
No Relationships to Disclose
 
Shogo Nomura
Employment - Asahi Kasei (I)
 
Kohei Shitara
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Novartis; Takeda
Consulting or Advisory Role - Bayer (Inst); Chugai Pharma (Inst); Lilly (Inst); Takeda (Inst)
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Atsushi Ohtsu
Employment - Celgene (I)
Research Funding - Bristol-Myers Squibb
 
Takayuki Yoshino
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline K.K. (Inst)